Product Availability: In Stock (FedEx delivery within 2 business days).
Ordering: To place an order please use Add to Cart button (account not required).
Transfection Reagent for NCI-H292 Cells (Lung Carcinoma Cells, CRL-1848)
Two component formulation enhances lipid mediated transfection efficiency
Optimized easy-to-use transfection protocol provided for transfection of siRNA, DNA, mRNA, and microRNA
Kit includes Transfection Enhancer reagent and recommended transfection protocol
Expand your RNAi application with a reagent optimized for delivery of both siRNA and plasmid
Reproducible transfection results
Works well for standard reverse transfection and high-throughput applications
- Download NCI-H292 CRISPR/Cas9 transfection protocol: [PDF]
Download PowerPoint presentation for NCI-H292 cells transfection kit: [PPT]
- UPC/GTIN/EAN: 860002089703
Brand: ALTOGEN®, developed and manufactured by Altogen Biosystems
Reagent exhibits at least 93% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Transfection Protocol and MSDS:
Download Altogen Biosystems NCI-H292 Transfection Protocol: [PDF]
Download MSDS: [PDF]
NCI-H292 Cell Line:
NCI-H292 cells are sensitive for many different viruses, including herpes simplex virus, measles virus, mumps as well as some strains of influenza virus type A. This makes them an excellent substitute for MK cells with regard to laboratory safety, paramyxovirus isolation, and ease of use, according to the Journal of Clinical Microbiology (Jun 1993, Vol.31, pp. 1504–1510) The NCI-H292 tumorigenic cell line is derived from a lymph node metastasis lung cells of a 32-year-old female with mucoepidermoid pulmonary carcinoma and exhibits epithelial morphology. NCI-H292 cells have been negatively tested for L-DOPA decarboxylase and display the same mucoepidermoid characteristics as normal (non-cancerous) cells do. NCI-H292 cells susceptible to the Hepatitis B virus, making them valuable tools for biomedical research. This cell line is used as in vitro model in a variety of molecular and cell biology research related to lung cancer. Altogen Biosystems manufactures high-efficiency transfection reagent kits for this cell line.
NCI-H292 is a human pulmonary mucoepidermoid carcinoma cell line that was established from a lung tumor of a 58-year-old male patient in 1980. Mucoepidermoid carcinoma is a type of cancer that can occur in various organs, including the lungs, salivary glands, and thyroid gland. NCI-H292 cells have been widely used in respiratory research as a model for studying lung cancer and other lung diseases. They are commonly used to investigate the molecular mechanisms underlying lung cancer development, as well as to evaluate the efficacy of potential lung cancer therapies.NCI-H292 cells have a typical epithelial morphology and can be cultured as adherent monolayers in standard tissue culture conditions. They are known to express mucin-like glycoproteins, which are commonly found in lung epithelial cells, and are used as indicators of lung epithelial differentiation. NCI-H292 cells are commonly used in drug screening assays to identify potential anti-lung cancer drugs. They have been shown to be sensitive to a wide range of chemotherapeutic agents, including cisplatin, paclitaxel, and gemcitabine, which are commonly used in the treatment of lung cancer. Additionally, NCI-H292 cells have been used to test the efficacy of novel targeted therapies, such as tyrosine kinase inhibitors, in the treatment of lung cancer.
NCI-H292 cell line mutations:
Figure 1. GAPD mRNA levels were quantified using real-time RT-PCR in the NCI-H292 cells transfected with siRNAs targeting GAPD or non-silencing siRNA. Forty-eight hours post-transfection, the cells were harvested and analyzed by real-time RT-PCR for GAPD mRNA expression levels. Data were normalized against the 18S rRNA signal. Control samples were either mock-transfected or untreated. Values are normalized to untreated sample. Data are means ± SD (n=5).
Figure 2. Protein expression of GAPDH in NCI-H292 cells. DNA plasmid expressing GAPDH or siRNA targeting GAPDH were transfected into NCI-H292 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.
Altogen Biosystems is a life sciences company that offers cell type-specific and pre-optimized transfection products, electroporation kits, and in vivo delivery reagents. Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of protein, DNA, mRNA, shRNA and siRNA molecules. Read more about transfection technology at Altogen’s Transfection Resource.
Altogen Research Services:
Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).
- 0.5 ml (Catalog #6858)
- 1.5 ml (Catalog #6859)
- 1.5 ml CRISPR (Catalog #2179)
- 8.0 ml (Catalog #7013)